UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY - USD ($)	Total	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interests in Consolidated Subsidiaries	Redeemable Noncontrolling Interests
Balance at beginning of period at Dec. 31, 2021	$ 1,084,600,000	$ 1,070,500,000	$ 1,700,000	$ (820,300,000)	$ 237,800,000	$ 1,659,500,000	$ 8,200,000	$ 14,100,000	$ 200,000
Balance (in shares) at Dec. 31, 2021			150,753,687	24,151,348
Increase (Decrease) in Stockholders' Equity
Stock options exercised	3,100,000	3,100,000			3,100,000
Stock options exercised (in shares)			118,630
Restricted Stock units vested (in shares)			22,440
Stock based compensation	3,800,000	3,800,000			3,800,000
Shares Repurchased	(105,600,000)	(105,600,000)		$ (105,600,000)
Shares Repurchased (in shares)			(1,603,055)	1,603,055
Cash dividends paid to common shareholders	(7,500,000)	7,500,000				7,500,000
Proceeds from the sale of noncontrolling interests	0
Formation of Acuity Spatial Genomics Inc.									6,800,000
Consolidated net income	62,100,000	61,600,000				61,600,000		500,000
Other comprehensive income (loss)	(9,200,000)	(8,900,000)					(8,900,000)	(300,000)	(0.2)
Balance at end of period at Mar. 31, 2022	1,031,300,000	1,017,000,000.0	$ 1,700,000	$ (925,900,000)	244,700,000	1,713,600,000	(17,100,000)	14,300,000	6.8
Balance (in shares) at Mar. 31, 2022			149,291,702	25,754,403
Balance at beginning of period at Dec. 31, 2022	1,125,700,000	1,113,800,000	$ 1,700,000	$ (1,085,000,000.0)	256,300,000	1,926,000,000.0	14,800,000	11,900,000	6,100,000
Balance (in shares) at Dec. 31, 2022			147,023,144	28,366,442
Increase (Decrease) in Stockholders' Equity
Stock options exercised	700,000	700,000			700,000
Stock options exercised (in shares)			34,957
Restricted Stock units vested	(100,000)	(100,000)			(100,000)
Restricted Stock units vested (in shares)			18,463
Stock based compensation	4,100,000	4,100,000			4,100,000
Employee stock purchase plan	200,000	200,000			200,000
Shares Repurchased	(22,300,000)	22,300,000		$ 22,200,000	100,000
Shares Repurchased (in shares)			315,318	315,318
Cash dividends paid to common shareholders	(7,400,000)	7,400,000				(7,400,000)
Biogynosys acquisition - other shareholders									2,300,000
Other majority owned acquisition - other shareholders									3,600,000
Proceeds from the sale of noncontrolling interests	5,300,000							5,300,000
Consolidated net income	(77,500,000)	(76,500,000)				(76,500,000)		(1,000,000.0)	100,000
Other comprehensive income (loss)	15,100,000	14,800,000					14,800,000	300,000	100,000
Balance at end of period at Mar. 31, 2023	$ 1,198,800,000	$ 1,180,300,000	$ 1,700,000	$ (1,107,200,000)	$ 261,100,000	$ 1,995,100,000	$ 29,600,000	$ 18,500,000	$ 12,000,000.0
Balance (in shares) at Mar. 31, 2023			146,761,246	28,681,760